| Bioactivity | Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD)[1][2]. | |||||||||
| Target | Ki: 50 nM (σ receptor); IC50: 5.5 μM ( DA). | |||||||||
| Invitro | Opipramol can potently interact with sigma recognition sites with a Ki value of 50 nM[1]. Opipramol inhibit the uptake of [3H] DA in crude synaptosomal preparations with an IC50 value of 5.5 μM[1]. | |||||||||
| In Vivo | Opipramol (i.p.; 5-50 mg/kg) increases dopamine release in vivo[2]. Animal Model: | |||||||||
| Name | Opipramol | |||||||||
| CAS | 315-72-0 | |||||||||
| Formula | C23H29N3O | |||||||||
| Molar Mass | 363.50 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. H J Möller, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001 Feb;21(1):59-65. [2]. T S Rao, et al. Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo. Neuropharmacology. 1990 Dec;29(12):1191-7. |